Clinical Effect of Driver Mutations of KRAS, CDKN2A/P16, TP53 , and SMAD4 in Pancreatic Cancer: A Meta-Analysis

Practical methods for incorporating summary time-to-event data into meta-analysis.

Tierney, J. F., Stewart, L. A., Ghersi, D., Burdett, S., & Sydes, M. R. (2007) · Trials · doi:10.1186/1745-6215-8-16 · Cited by 6,208 · see citing works

TIMER: A Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune Cells

Li, T., Fan, J., Wang, B., Traugh, N. C., Chen, Q., Liu, J. S., Li, B., & Liu, X. S. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0307 · Cited by 5,914 · see citing works

TIMER2.0 for analysis of tumor-infiltrating immune cells

Li, T., Fu, J., Zeng, Z., Cohen, D., Li, J., Chen, Q., Li, B., & Liu, X. S. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa407 · Cited by 5,219 · see citing works

Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints.

Parmar, M. K. B., Torri, V., & Stewart, L. (1998) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(19981230)17:24 · Cited by 4,519 · see citing works

Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses

Jones, S., Zhang, X., Parsons, D. W., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Kamiyama, H., Jimeno, A., et al. (2008) · Science · doi:10.1126/science.1164368 · Cited by 3,969 · see citing works

Whole genomes redefine the mutational landscape of pancreatic cancer

Initiative, A. P. C. G., Waddell, N., Pajic, M., Patch, A.-M., Chang, D. K., Kassahn, K. S., Bailey, P., Johns, A. L., Miller, D., Nones, K., et al. (2015) · Nature · doi:10.1038/nature14169 · Cited by 2,642 · cited 1× · see citing works

Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer

Kamerkar, S., LeBleu, V. S., Sugimoto, H., Yang, S., Ruivo, C. F., Melo, S. A., Lee, J. J., & Kalluri, R. (2017) · Nature · doi:10.1038/nature22341 · Cited by 2,639 · see citing works

Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice

Hingorani, S. R., Wang, L., Multani, A. S., Combs, C., Deramaudt, T. B., Hruban, R. H., Rustgi, A. K., Chang, S., & Tuveson, D. A. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.04.023 · Cited by 2,609 · see citing works

Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse

Hingorani, S. R., Petricoin, E. F., Maitra, A., Rajapakse, V., King, C., Jacobetz, M. A., Ross, S., Conrads, T. P., Veenstra, T. D., Hitt, B. A., et al. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00309-x · Cited by 2,471 · see citing works

Pancreatic cancer

Kamisawa, T., Wood, L. D., Itoi, T., & Takaori, K. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00141-0 · Cited by 2,212 · see citing works

Germline p16 mutations in familial melanoma

Hussussian, C. J., Struewing, J. P., Goldstein, A. M., Higgins, P., Ally, D. S., Sheahan, M. D., Clark, W. H., Tucker, M. A., & Dracopoli, N. C. (1994) · Nature Genetics · doi:10.1038/ng0994-15 · Cited by 1,252 · see citing works

Aggregate data meta‐analysis with time‐to‐event outcomes

Williamson, P. R., Smith, C. T., Hutton, J. L., & Marson, A. G. (2002) · Statistics in Medicine · doi:10.1002/sim.1303 · Cited by 551 · see citing works

Pancreatic Cancer Surgery

Strobel, O., Hank, T. P., Hinz, U., Bergmann, F., Schneider, L., Springfeld, C., Jäger, D., Schirmacher, P., Hackert, T., & Büchler, M. W. (2016) · Annals of Surgery · doi:10.1097/sla.0000000000001731 · Cited by 346 · see citing works

KRAS, TP53, CDKN2A, SMAD4, BRCA1, and BRCA2 Mutations in Pancreatic Cancer

Cicenas, J., Kvederavičiūtė, K., Meskinyte, I., Meškinytė-Kaušilienė, E., Skeberdytė, A., & Cicenas, J. (2017) · Cancers · doi:10.3390/cancers9050042 · Cited by 273 · see citing works

Immunohistochemically Detected Expression of 3 Major Genes (CDKN2A/p16, TP53, and SMAD4/DPC4) Strongly Predicts Survival in Patients With Resectable Pancreatic Cancer

Oshima, M., Okano, K., Muraki, S., Haba, R., Maeba, T., Suzuki, Y., & Yachida, S. (2013) · Annals of Surgery · doi:10.1097/sla.0b013e3182827a65 · Cited by 236 · see citing works

Cell cycle activation by c-myc in a Burkitt lymphoma model cell line

Pajic, A., Spitkovsky, D., Christoph, B., Kempkes, B., Schuhmacher, M., Staege, M. S., Brielmeier, M., Ellwart, J. W., Kohlhuber, F., Bornkamm, G. W., et al. (2000) · International Journal of Cancer · doi:10.1002/1097-0215(20000915)87:6 · Cited by 204 · see citing works

The prognostic value of GLUT1 in cancers: a systematic review and meta-analysis

Yu, M., Yongzhi, H., Chen, S., Luo, X., Lin, Y., Zhou, Y., Jin, H., Hou, B., Deng, Y., Tu, L., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.17445 · Cited by 167 · see citing works

<i>DPC4</i>/Smad4 Expression and Outcome in Pancreatic Ductal Adenocarcinoma

Biankin, A. V., Morey, A. L., Lee, C.-S., Kench, J. G., Biankin, S. A., Hook, H. C., Head, D. R., Hugh, T. B., Sutherland, R. L., & Henshall, S. M. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.12.063 · Cited by 163 · see citing works

Impact of <i>KRAS</i> Mutations on Clinical Outcomes in Pancreatic Cancer Patients Treated with First-line Gemcitabine-Based Chemotherapy

Kim, S. T., Lim, D. H., Jang, K.-T., Lim, T., Lee, J., Choi, Y.-L., Jang, H.-L., Yi, J. H., Baek, K. K., Park, S. H., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0269 · Cited by 145 · see citing works

Correlation of total VEGF mRNA and protein expression with histologic type, tumor angiogenesis, patient survival and timing of relapse in non-small-cell lung cancer

Yuan, A., Yu, C., Chen, W., Lin, F., Kuo, S.-H., Luh, K., & Yang, P. (2000) · International Journal of Cancer · doi:10.1002/1097-0215(20001120)89:6 · Cited by 138 · see citing works

Infiltrating immune cells and gene mutations in pancreatic ductal adenocarcinoma

Wang, W.-Q., Liu, L., Xu, H.-X., Wu, C.-T., Xiang, J.-F., Xu, J., Liu, C., Long, J., Ni, Q.-X., & Yu, X. (2016) · British journal of surgery · doi:10.1002/bjs.10187 · Cited by 111 · see citing works

EGFR pathway biomarkers in erlotinib-treated patients with advanced pancreatic cancer: translational results from the randomised, crossover phase 3 trial AIO-PK0104

Boeck, S. H., Jung, A., Laubender, R. P., Neumann, J. H. L., Egg, R., Goritschan, C., Vehling‐Kaiser, U., Winkelmann, C., von Weikersthal, L. F., Clemens, M., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.495 · Cited by 107 · see citing works

Genetic Alterations of K-ras, p53, c-erbB-2, and DPC4 in Pancreatic Ductal Adenocarcinoma and Their Correlation With Patient Survival

Shin, S. H., Kim, S. C., Hong, S.-M., Kim, Y. H., Song, K.-B., Park, K.-M., & Lee, Y.-J. (2013) · Pancreas · doi:10.1097/mpa.0b013e31825b6ab0 · Cited by 107 · see citing works

Curation of the Pancreatic Ductal Adenocarcinoma Subset of the Cancer Genome Atlas Is Essential for Accurate Conclusions about Survival-Related Molecular Mechanisms

Peran, I., Madhavan, S., Byers, S. W., & McCoy, M. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0290 · Cited by 96 · see citing works

p16INK4a is a Prognostic Marker in Resected Ductal Pancreatic Cancer

Gerdes, B., Ramaswamy, A., Ziegler, A., Lang, S. A., Kersting, M., Baumann, R., Wild, A., Moll, R., Rothmund, Μ., & Bartsch, D. K. (2002) · Annals of Surgery · doi:10.1097/00000658-200201000-00007 · Cited by 89 · see citing works

Utility of Assessing the Number of Mutated KRAS, CDKN2A, TP53, and SMAD4 Genes Using a Targeted Deep Sequencing Assay as a Prognostic Biomarker for Pancreatic Cancer

Hayashi, H., Kohno, T., Ueno, H., Hiraoka, N., Kondo, S., Saito, M., Shimada, Y., Ichikawa, H., Kato, M., Shibata, T., et al. (2017) · Pancreas · doi:10.1097/mpa.0000000000000760 · Cited by 88 · see citing works

Having Pancreatic Cancer with Tumoral Loss of ATM and Normal TP53 Protein Expression Is Associated with a Poorer Prognosis

Kim, H., Saka, B., Knight, S., Borges, M. W., Childs, E. J., Klein, A. P., Wolfgang, C. L., Herman, J. M., Adsay, V. N., Hruban, R. H., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1239 · Cited by 85 · see citing works

KRAS mutation status is not predictive for objective response to anti-EGFR treatment with erlotinib in patients with advanced pancreatic cancer

Boeck, S., Jung, A., Laubender, R. P., Neumann, J., Egg, R., Goritschan, C., Ormanns, S., Haas, M., Modest, D. P., Kirchner, T., et al. (2013) · Journal of Gastroenterology · doi:10.1007/s00535-013-0767-4 · Cited by 77 · see citing works

Genome-Wide Characterization of Pancreatic Adenocarcinoma Patients Using Next Generation Sequencing

Liang, W. S., Craig, D. W., Carpten, J. D., Borad, M. J., Demeure, M. J., Weiss, G. J., Izatt, T., Sinari, S. A., Christoforides, A., Aldrich, J., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0043192 · Cited by 73 · see citing works

High expression of RAB27A and TP53 in pancreatic cancer predicts poor survival

Wang, Q., Ni, Q., Wang, X., Zhu, H., Wang, Z., & Huang, J. (2015) · Medical Oncology · doi:10.1007/s12032-014-0372-2 · Cited by 70 · see citing works

Loss of DPC4 expression and its correlation with clinicopathological parameters in pancreatic carcinoma

Hua, Z. (2003) · World Journal of Gastroenterology · doi:10.3748/wjg.v9.i12.2764 · Cited by 55 · see citing works

Loss of SMAD4 staining in pre-operative cell blocks is associated with distant metastases following pancreaticoduodenectomy with venous resection for pancreatic cancer

Boone, B. A., Sabbaghian, S., Zenati, M. S., Marsh, J. W., Moser, A. J., Zureikat, A. H., Singhi, A. D., Zeh, H. J., & Krasinskas, A. M. (2014) · Journal of Surgical Oncology · doi:10.1002/jso.23606 · Cited by 49 · see citing works

Correlation Between RAB27B and p53 Expression and Overall Survival in Pancreatic Cancer

Zhao, H., Wang, Q., Wang, X., Zhu, H., Zhang, S., Wang, W., Wang, Z. P., & Huang, J. (2015) · Pancreas · doi:10.1097/mpa.0000000000000453 · Cited by 49 · see citing works

Prognostic factors in resectable pancreatic cancer: p53 and Bcl-2

Bold, R. J., Hess, K. R., Pearson, A. S., Grau, A. M., Sinicrope, F. A., Jennings, M., McConkey, D. J., Bucana, C. D., Cleary, K. R., Hallin, P. A., et al. (1999) · Journal of Gastrointestinal Surgery · doi:10.1016/s1091-255x(99)80068-7 · Cited by 48 · see citing works

The Expression of S100A4 in Human Pancreatic Cancer Is Associated With Invasion

Tsukamoto, N., Egawa, S., Akada, M., Abe, K., Saiki, Y., Kaneko, N., Yokoyama, S., Shima, K., Yamamura, A., Motoi, F., et al. (2013) · Pancreas · doi:10.1097/mpa.0b013e31828804e7 · Cited by 47 · see citing works

Abnormalities of Tumor Suppressor Gene p16 in Pancreatic Carcinoma : Immunohistochemical and Genetic Findings Compared with Clinicopathological Parameters

Ohtsubo, K., Hiroyuki, W., Yamaguchi, Y., & Norio, S. (2003) · Kanazawa University Repository for Academic Resources (DSpace) (Kanazawa University) · Cited by 47 · see citing works

Pancreatic Cancer Progression Relies upon Mutant p53-Induced Oncogenic Signaling Mediated by NOP14

Du, Y., Liu, Z., You, L., Hou, P., Ren, X., Jiao, T., Zhao, W., Li, Z., Shu, H., Liu, C., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-2339 · Cited by 46 · see citing works

Prognostic Biomarkers in Pancreatic Cancer: Avoiding Errata When Using the TCGA Dataset

Nicolle, R., Raffenne, J., Paradis, V., Couvelard, A., de Reyniès, A., Blum, Y., & Cros, J. F. (2019) · Cancers · doi:10.3390/cancers11010126 · Cited by 45 · see citing works

Clinical Significance of p16 Protein Expression Loss and Aberrant p53 Protein Expression in Pancreatic Cancer

Jeong, J., Park, Y. N., Park, J. S., Yoon, D. S., Chi, H. S., & Kim, B. R. (2005) · Yonsei Medical Journal · doi:10.3349/ymj.2005.46.4.519 · Cited by 44 · see citing works

KRAS Mutations in Codon 12 or 13 Are Associated With Worse Prognosis in Pancreatic Ductal Adenocarcinoma

Sinn, B. V., Striefler, J. K., Rudl, M., Lehmann, A., Bahra, M., Denkert, C., Sinn, M., Stieler, J., Klauschen, F., Budczies, J., et al. (2014) · Pancreas · doi:10.1097/mpa.0000000000000077 · Cited by 43 · see citing works

The prognostic value of TP53 mutations in oesophageal adenocarcinoma: a systematic review and meta-analysis

Fisher, O. M., Lord, S. J., Falkenback, D., Clemons, N. J., Eslick, G. D., & Lord, R. V. (2016) · Gut · doi:10.1136/gutjnl-2015-310888 · Cited by 43 · see citing works

Expression of Bcl‐2 and p53 protein in resectable invasive ductal carcinoma of the pancreas: Effects on clinical outcome and efficacy of adjuvant chemotherapy

Nio, Y., Dong, M., Iguchi, C., Yamasawa, K., Toga, T., Itakura, M., & Tamura, K. (2001) · Journal of Surgical Oncology · doi:10.1002/jso.1033 · Cited by 40 · see citing works

Simvastatin delay progression of pancreatic intraepithelial neoplasia and cancer formation in a genetically engineered mouse model of pancreatic cancer

Fendrich, V., Sparn, M. B., Lauth, M., Knoop, R. F., Plaßmeier, L., Bartsch, D. K., & Waldmann, J. (2013) · Pancreatology · doi:10.1016/j.pan.2013.08.002 · Cited by 38 · see citing works

Multivariate analysis of immunohistochemical evaluation of protein expression in pancreatic ductal adenocarcinoma reveals prognostic significance for persistent Smad4 expression only

Ottenhof, N. A., Morsink, F. H. M., ten Kate, F. J. W., Noorden, C. J. F. V., & Offerhaus, G. J. A. (2012) · Cellular Oncology · doi:10.1007/s13402-012-0072-x · Cited by 38 · see citing works

The Genomic Landscape of Pancreatic and Periampullary Adenocarcinoma

Sandhu, V., Wedge, D. C., Lothe, I. M. B., Labori, K. J., Dentro, S. C., Buanes, T. A., Skrede, M. L., Dalsgaard, A. M., Munthe, E., Myklebost, O., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0658 · Cited by 37 · see citing works

Clinical study of genomic drivers in pancreatic ductal adenocarcinoma

Barrett, M. T., Deiotte, R., Lenkiewicz, E., Malasi, S., Holley, T., Evers, L., Posner, R. G., Jones, T., Han, H., Sausen, M., et al. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.209 · Cited by 37 · see citing works

Understanding pancreatic cancer genomes

Cowley, M. J., Chang, D. K.-F., Pajic, M., Johns, A. L., Waddell, N., Grimmond, S. M., & Biankin, A. V. (2013) · Journal of Hepato-Biliary-Pancreatic Sciences · doi:10.1007/s00534-013-0610-6 · Cited by 36 · see citing works

Role of surgery in pancreatic cancer

Buanes, T. A. (2017) · World Journal of Gastroenterology · doi:10.3748/wjg.v23.i21.3765 · Cited by 36 · see citing works

p21WAF1 expression is associated with improved survival after adjuvant chemoradiation for pancreatic cancer

Ahrendt, S. A., Brown, H. M., KOMOROWSKI, R. A., Zhu, Y.-R., Wilson, S. D., Erickson, B. A., Ritch, P. S., Pitt, H. A., & Demeure, M. J. (2000) · Surgery · doi:10.1067/msy.2000.108052 · Cited by 36 · see citing works

pERK, pAKT and p53 as tissue biomarkers in erlotinib-treated patients with advanced pancreatic cancer: a translational subgroup analysis from AIO-PK0104

Ormanns, S., Siveke, J. T., Heinemann, V., Haas, M., Sipos, B., Schlitter, A. M., Esposito, I., Jung, A., Laubender, R. P., Krüger, S., et al. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-624 · Cited by 32 · see citing works

P53 overexpression and Ki67-index are associated with outcome in ductal pancreatic adenocarcinoma with adjuvant gemcitabine treatment

Striefler, J. K., Sinn, M., Pelzer, U., Jühling, A., Wisłocka, L., Bahra, M., Sinn, B. V., Denkert, C., Dörken, B., Oettle, H., et al. (2016) · Pathology - Research and Practice · doi:10.1016/j.prp.2016.06.001 · Cited by 31 · see citing works

Targeting Pancreatic Cancer Cell Plasticity: The Latest in Therapeutics

Smigiel, J. M., Parameswaran, N., & Jackson, M. W. (2018) · Cancers · doi:10.3390/cancers10010014 · Cited by 31 · see citing works

Elevated Transcript Levels From the MDM2 P1 Promoter and Low p53 Transcript Levels Are Associated With Poor Prognosis in Human Pancreatic Ductal Adenocarcinoma

Grochola, L. F., Taubert, H. W., Greither, T., Bhanot, U. K., Udelnow, A., & Würl, P. (2010) · Pancreas · doi:10.1097/mpa.0b013e3181f95104 · Cited by 31 · see citing works

Driver mutations

Korc, M. (2010) · Cancer Biology & Therapy · doi:10.4161/cbt.10.6.13128 · Cited by 26 · see citing works

Notch1 Is Not Required for Acinar-to-Ductal Metaplasia in a Model of Kras-Induced Pancreatic Ductal Adenocarcinoma

Avila, J. L., Troutman, S. A., Durham, A. C., & Kissil, J. L. (2012) · PLoS ONE · doi:10.1371/journal.pone.0052133 · Cited by 25 · see citing works

Current developments, problems and solutions in the non-surgical treatment of pancreatic cancer

Guo, X., Cui, Z.-M., & Liu, X. (2013) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v5.i2.20 · Cited by 24 · see citing works

MYC: A Stratification Marker for Pancreatic Cancer Therapy

Wirth, M., & Schneider, G. (2015) · Trends in cancer · doi:10.1016/j.trecan.2015.12.002 · Cited by 23 · see citing works

Pancreatic cancer screening: Still a delusion?

Moutinho-Ribeiro, P., Coelho, R., Giovannini, M. F., & Macedo, G. (2017) · Pancreatology · doi:10.1016/j.pan.2017.07.001 · Cited by 21 · see citing works

Expression of Gadd45a and p53 proteins in human pancreatic cancer: Potential effects on clinical outcomes

Dong, M., Dong, Q., Zhang, H., Zhou, J., Tian, Y., & Dong, Y. (2007) · Journal of Surgical Oncology · doi:10.1002/jso.20684 · Cited by 18 · see citing works

Cyclin D1, p16INK4Aand p27Kip1in pancreatic adenocarcinoma: assessing prognostic implications through quantitative image analysis

Georgiadou, D., Sergentanis, T. Ν., Sakellariou, S., Filippakis, G. M., Zagouri, F., Vlachodimitropoulos, D. G., Ψαλτοπούλου, Θ., Lazaris, A. C., Patsouris, E., & Zografos, G. (2014) · Apmis · doi:10.1111/apm.12289 · Cited by 15 · see citing works

Pancreatic cancer screening

SOLDAN, M. (2017) · Revista do Colégio Brasileiro de Cirurgiões · doi:10.1590/0100-69912017002015 · Cited by 11 · see citing works

Recent Advances in Pancreatic Cancer Surgery of Relevance to the Practicing Pathologist

van Rijssen, L. B., Rombouts, S. J. E., Walma, M. S., Vogel, J. A., Tol, J. A. M. G., Molenaar, I. Q., van Eijck, C. H. J., Verheij, J., van de Vijver, M. J., Busch, O. R., et al. (2016) · Surgical pathology clinics · doi:10.1016/j.path.2016.05.002 · Cited by 10 · see citing works

Neoadjuvant Treatment in Locally Advanced and Borderline Resectable Pancreatic Cancer vs Primary Resectable Pancreatic Cancer

Chiaro, M. D., Valente, R., & Arnelo, U. (2017) · JAMA Surgery · doi:10.1001/jamasurg.2017.2228 · Cited by 9 · see citing works

PDAC metastases show identical known driver gene mutations

Dickson, I. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.9 · Cited by 5 · see citing works

Resektabilitätskriterien beim Pankreaskarzinom und postoperative Bildgebung

Grenacher, L., & Juchems, M. S. (2017) · Der Radiologe · doi:10.1007/s00117-017-0326-8 · Cited by 3 · see citing works

Significance of TP53, CDKN2A, SMAD4 and KRAS in Pancreatic Cancer

Stefanoudakis, D., Frountzas, M., Schizas, D., Michalopoulos, N. V., Drakaki, A., & Toutouzas, K. G. (2024) · Current Issues in Molecular Biology · doi:10.3390/cimb46040177 · Cited by 110 · see citing works

TGFβ Signaling in the Pancreatic Tumor Microenvironment

Principe, D. R., Timbers, K. E., Atia, L. G., Koch, R. M., & Rana, A. (2021) · Cancers · doi:10.3390/cancers13205086 · Cited by 86 · see citing works

KRAS G12D Mutation Subtype in Pancreatic Ductal Adenocarcinoma: Does It Influence Prognosis or Stage of Disease at Presentation?

Shen, H., Lundy, J., Strickland, A. H., Harris, M., Swan, M. P., Desmond, C., Jenkins, B. J., & Croagh, D. G. (2022) · Cells · doi:10.3390/cells11193175 · Cited by 56 · see citing works

Elevated expression of nuclear receptor-binding SET domain 3 promotes pancreatic cancer cell growth

Sun, Y., Xie, J., Cai, S., Wang, Q., Feng, Z., Li, Y., Lu, J., Chen, W., & Ye, Z. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-04205-6 · Cited by 28 · see citing works

Investigating underlying molecular mechanisms, signaling pathways, emerging therapeutic approaches in pancreatic cancer

Mustafa, M., Abbas, K., Alam, M., Habib, S., Zulfareen, Hasan, G., Islam, S., Shamsi, A., & Hassan, I. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1427802 · Cited by 24 · see citing works

New insight into the role of SMAD4 mutation/deficiency in the prognosis and therapeutic resistance of pancreatic ductal adenocarcinomas

Yao, H.-J., Luo, L., Li, R. Q., Zhao, Y., Zhang, L., Pešić, M., Cai, L., & Li, L. (2024) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2024.189220 · Cited by 19 · see citing works

Obesity associated pancreatic ductal adenocarcinoma: Therapeutic challenges

Srilatha, M., Malla, R. R., Adem, M. P., Foote, J. B., & Nagaraju, G. P. (2023) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2023.11.002 · Cited by 18 · see citing works

Clinical Applications of Classical and Novel Biological Markers of Pancreatic Cancer

Pekarek, L., Fraile‐Μartinez, O., Montero, C. G., Sáez, M. A., Barquero-Pozanco, I., del Hierro-Marlasca, L., Castro-Martinez, P. D., Romero-Bazán, A., Álvarez-Mon, M. Á., Monserrat, J., et al. (2022) · Cancers · doi:10.3390/cancers14081866 · Cited by 18 · see citing works

Cuprotosis-related signature predicts overall survival in clear cell renal cell carcinoma

Zhang, F., Lin, J., Feng, D., Liang, J., Lu, Y., Liu, Z., & Wang, X. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.922995 · Cited by 14 · see citing works

Therapeutic Aspects and Molecular Targets of Autophagy to Control Pancreatic Cancer Management

Rahman, M. A., Ahmed, K. R., Rahman, M. H., Parvez, M. A. K., Lee, I., & Kim, B. (2022) · Biomedicines · doi:10.3390/biomedicines10061459 · Cited by 12 · see citing works

Review of Current Systemic Therapy and Novel Systemic Therapy for Pancreatic Ductal Adenocarcinoma

Sarfraz, H. R., Saha, A., Jhaveri, K. S., & Kim, D. W. (2023) · Current Oncology · doi:10.3390/curroncol30060404 · Cited by 11 · see citing works

Recent Anti-KRASG12D Therapies: A “Possible Impossibility” for Pancreatic Ductal Adenocarcinoma

Sobhani, N., Pittacolo, M., D’Angelo, A., & Marchegiani, G. (2025) · Cancers · doi:10.3390/cancers17040704 · Cited by 11 · see citing works

Prognostic value of the TP53 mutation in patients with pancreatic ductal adenocarcinoma receiving FOLFIRINOX

Kim, M. K., Cho, I. R., Kim, Y., Choi, J. H., Jung, K., Kim, J., Kim, S., Yun, H., Yoon, J., Oh, D. Y., et al. (2024) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359241290482 · Cited by 8 · see citing works

The role of diagnostic, prognostic, and predictive biomarkers in the management of early pancreatic cancer

Maloney, S., Clarke, S. J., Sahni, S., Hudson, A. L., Colvin, E. K., Mittal, A., Samra, J. S., & Pavlakis, N. (2023) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-023-05149-4 · Cited by 5 · see citing works

Research insights into the chemokine-like factor (CKLF)-like MARVEL transmembrane domain-containing family (CMTM): their roles in various tumors

Duan, S., Jiang, Y., Li, G., Fu, W., Song, Z., Li, L.-N., & Li, J. (2024) · PeerJ · doi:10.7717/peerj.16757 · Cited by 5 · see citing works

Molecular Biomarkers for the Diagnosis and Prognostication of Pancreatic Ductal Adenocarcinoma

Sun, J. X., Awad, M. A., Hwang, J., & Villano, A. M. (2025) · Journal of Personalized Medicine · doi:10.3390/jpm15060236 · Cited by 3 · see citing works

Association between SMAD4 Mutations and GATA6 Expression in Paired Pancreatic Ductal Adenocarcinoma Tumor Specimens: Data from Two Independent Molecularly-Characterized Cohorts

Greendyk, J. D., Allen, W. E., Alexander, H. R., Beninato, T., Eskander, M. F., Grandhi, M. S., Kennedy, T. J., Langan, R. C., Maggi, J. C., De, S., et al. (2023) · Biomedicines · doi:10.3390/biomedicines11113058 · Cited by 3 · see citing works

Smad4 Heterozygous Knockout Effect on Pancreatic and Body Weight in F1 Population Using Collaborative Cross Lines

Zohud, O., Lone, I. M., Midlej, K., Nashef, A., & Iraqi, F. A. (2024) · Biology · doi:10.3390/biology13110918 · Cited by 2 · see citing works

SKIL Promotes Pancreatic Cancer Metastasis by Inhibiting TSPYL2 to Activate the TGF‐β Pathway

Wang, C., Song, W., Zhang, Y., Deng, H., Zhou, Z., Zhu, J., & Wang, X. (2025) · Cancer Innovation · doi:10.1002/cai2.70011 · Cited by 2 · see citing works

Predictors of patients with advanced pancreatic cancer undergoing conversion surgery via chemoimmunotherapy with a multifunctional Wilms’ tumor 1 (WT1) peptide cocktail-pulsed dendritic cell vaccine

Koido, S., Taguchi, J., Shimabuku, M., Bito, T., Morimoto, S., Oji, Y., Oka, Y., Ito, M., Shimizu, Y., Ito, Z., et al. (2025) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-011426 · Cited by 2 · see citing works

Nab-Paclitaxel-Loaded Poly (Lactic-Co-Glycolic Acid) Nanoparticles as Microtubule B-Tubulin Stabilizer in the Management of Pancreatic Cancer

de Liyis, B. G., Mareska, V., AHMAD, C. A., WINDIARTO, A. C., & Indrayani, A. W. (2023) · Journal of Oncological Sciences · doi:10.37047/jos.2022-94097 · Cited by 1 · see citing works

Prognostic value of KRAS gene mutations in pancreatic ductal adenocarcinoma: a systematic review and meta-analysis

Aslani, S., LEE, B. T. O., Strickland, A., Shen, H., & Croagh, D. G. (2026) · Scandinavian Journal of Gastroenterology · doi:10.1080/00365521.2025.2610630 · Cited by 1 · see citing works

Peptides as integrative modulators for clinical prognosis and targeted therapy in pancreatic cancer

Yadav, B., Kollur, S. P., Ali, A., Arora, P., Gupta, A., Saranraj, P., Upadhye, V. J., & Singh, P. (2026) · Discover Oncology · doi:10.1007/s12672-026-05130-w · Cited by 1 · see citing works

NECTIN4 (PVRL4) expression in pancreatic cancer patients might be associated with a more unfavorable prognosis, independent of age at diagnosis, sex, and stage: A public microarray and RNA sequencing data based bioinformatics analysis

Yay, F., & Kan, M. U. (2026) · Computational Biology and Chemistry · doi:10.1016/j.compbiolchem.2026.109306 · Cited by 1 · see citing works

Recent advancement in molecular markers of pancreatic cancer

Paul, L. T. D., Munuswamy‐Ramanujam, G., Kumar, R. C. S., Ramachandran, V., Gnanasampanthapandian, D., & Palaniyandi, K. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-95114-2.00025-x

Advances in Biomarkers for Pancreatic Cancer

Zou, Y., Li, Y., & Zou, C. (2025) · Journal of Biosciences and Medicines · doi:10.4236/jbm.2025.135019

Prognostic role and clinicopathological features of SMAD4 gene mutation in pancreatic cancer: a systematic review and meta-analysis

Rodrigues, T., Albuquerque, J., Cardoso, J., Sousa-Ferreira, I., Martins, J. P., & Coelho, J. L. P. (2026) · Cancer Treatment and Research Communications · doi:10.1016/j.ctarc.2025.101091

Unexpected Long-Term Survival in Resected Pancreatic Ductal Adenocarcinoma Harboring KRAS G12R with an Ultra-Low-VAF SMAD4 Mutation: A Case Report and Mini-Review

Varzaru, B., Croitoru, A. E., Sorop, A., Lupescu, I. G., Dima, S., Iacob, R. A., Becheanu, G., & Gheorghe, C. (2026) · Reports — Medical Cases Images and Videos · doi:10.3390/reports9030285

Gene Mutation Profile of Pancreatic Cancer in Japanese Patients and Its Association with Prognosis

Hayashi, H., Ueno, H., Sakamoto, Y., Kondo, S., Morizane, C., Shimada, K., Ichikawa, H., Hiraoka, N., Kohno, T., & Okusaka, T. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu435.79

Post-operative mortality and recurrence patterns in pancreatic cancer according to KRAS mutation and CDKN2A, p53, and SMAD4 expression

Yohei, M., Manabu, T., Mariko, T., Kensuke, H., Yosuke, I., Tsuyoshi, H., Tatsunori, S., Jun’ichi, A., Yuki, H., Kawaguchi, Y., et al. (2023) · Institutional Repositories DataBase (IRDB)

Utility of Assessing the Number of Mutated KRAS, CDKN2A, TP53, and SMAD4 Genes Using a Targeted Deep Sequencing Assay as a Prognostic Biomarker for Pancreatic Cancer

Hayashi, H., Kohno, T., Ueno, H., Hiraoka, N., Kondo, S., Saito, M., Shimada, Y., Ichikawa, H., Kato, M., Shibata, T., et al. (2017) · Pancreas · doi:10.1097/mpa.0000000000000760 · Cited by 88 · see citing works

KRAS, CDKN2A, TP53, And SMAD4 Alterations in Relation to Postoperative Survival and Recurrence Patterns Among Patients with Pancreatic CancerPreprint

Masugi, Y., Takamatsu, M., Tanaka, M. H., Hara, K., Inoue, Y., Hamada, T., Suzuki, T., Arita, J., Hirose, Y., Kawaguchi, Y., et al. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4197932

a systematic review and meta-analysis

Rodrigues, T., Albuquerque, J., Cardoso, J., Sousa-Ferreira, I., Martins, J. P., & Coelho, J. L. P. (2026) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT)